Mark Joseph Eliason
( out of 1185 reviews )

Mark Joseph Eliason, MD

Languages spoken: English

Clinical Locations

Midvalley Health Center

Murray
801-581-2955
Directions

Sugar House Health Center

Salt Lake City
801-581-2000
Directions

University of Utah Hospital

Dermatology, Area E
Salt Lake City
801-581-2955
Directions

  • Mark Eliason, MD has specialized interest in skin cancer and inflammatory diseases of the skin. He is board certified in dermatology. He has completed a two-year fellowship in familial melanoma genetics and published research in this area. In addition, he has interest in inflammatory diseases such as urticaria and eczema. He sees patients for any general dermatologic concerns.

    Specialties

    Board Certification

    American Board of Dermatology (Dermatology)

    Patient Rating

    5.0 /5
    ( out of 1185 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    January 25, 2025
    SUGAR HOUSE HEALTH CENTER

    Mark is very good at what he does. He tries to be as thorough as possible in identifying and treating potential problems before they became serious problems.

    January 25, 2025
    MIDVALLEY

    Dr. Eliason is the best physician from any genre I have gone to. Caring, thorough, takes the time to talk about my concerns and explain everything that is easy to understand. Very efficient, never have to wait long.

    January 24, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr Eliason takes the time to talk to you so that you are well informed. He is very kind and respectful.

    January 24, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr. Eliason is extremely knowledgeable and extremly kind.

    January 23, 2025
    UNIVERSITY HOSPITAL

    Dr. Eliason is a wonderful, caring doctor. He really listens and explains things in a very understandable way.

    January 20, 2025
    UNIVERSITY HOSPITAL

    Awesome

    January 20, 2025
    SUGAR HOUSE HEALTH CENTER

    I would recommend Dr eliason

    January 19, 2025
    MIDVALLEY

    Amazing and caring person and doctor!

    January 18, 2025
    SUGAR HOUSE HEALTH CENTER

    A gentleman and a really good doctor

  • Mark Eliason, MD has specialized interest in skin cancer and inflammatory diseases of the skin. He is board certified in dermatology. He has completed a two-year fellowship in familial melanoma genetics and published research in this area. In addition, he has interest in inflammatory diseases such as urticaria and eczema. He sees patients for any general dermatologic concerns.

    Board Certification and Academic Information

    Academic Departments Dermatology -Professor (Clinical)
    Board Certification
    American Board of Dermatology (Dermatology)

    Education history

    Residency Dermatology - University of Utah School of Medicine Resident
    Research Fellow Familial Melanoma - Huntsman Cancer Institute Research Fellow
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Professional Medical Medicine - University of California - Irvine M.D.
    Undergraduate Molecular Biology - Brigham Young University B.S.

    Selected Publications

    Journal Article

    1. Carlisle RP, Flint ND, Hopkins ZH, Eliason MJ, Duffin KC, Secrest AM (2020). Administrative Burden and Costs of Prior Authorizations in a Dermatology Department. JAMA Dermatol, 156(10), 1074-1078. (Read full article)
    2. Forbes B, Secrest AM, Hand MQ, Eliason MJ (2018). Process of Post-operative Telephone Follow-up Implementation for Mohs Micrographic Surgery: A Pilot Study. J Clin Aesthet Dermatol, 11(7), 36-39. (Read full article)
    3. Clark JJ, Woodcock A, Cipriano SD, Hyde MA, Edwards SL, Frost CJ, Eliason MJ (2016). Community perceptions about the use of black salve. J Am Acad Dermatol, 74(5), 1021-3. (Read full article)
    4. Eliason MJ, Sontheimer RD (2015). How to reduce out-of-pocket costs for prescription medications.LID - 13030/qt5bk5n1vj [pii]. Dermatol Online J, 21(6). (Read full article)
    5. Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD (2012). A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol, 67(4), 680-6. (Read full article)
    6. Pho LN, Eliason MJ, Regruto M, Hull CM, Powell DL (2011). Treatment of chronic urticaria with colchicine. J Drugs Dermatol, 10(12), 1423-8. (Read full article)
    7. Pho LN, Smith FJ, Konecki D, Bale S, McLean WH, Cohen B, Eliason MJ, Leachman SA (2011). Paternal germ cell mosaicism in autosomal dominant pachyonychia congenita. Arch Dermatol, 147(9), 1077-80. (Read full article)
    8. Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL (2011). Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J Am Acad Dermatol, 64(6), 1221-2. (Read full article)
    9. McLean WH, Hansen CD, Eliason MJ, Smith FJ (2011). The phenotypic and molecular genetic features of pachyonychia congenita. J Invest Dermatol, 131(5), 1015-7. (Read full article)
    10. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 18(2), 442-6. (Read full article)
    11. Eliason MJ, Bowen GM, Bowen AR, Hazzard L, Samlowski WE (2009). Primary Treatment of Verrucous Carcinoma of the Penis with 5-fluorouracil, cis-diamino-dichloro platinum and Radiation Therapy Arch Derm). Arch Dermatol, 145(11), 1291.
    12. Larson AA, Leachman SA, Eliason MJ, Cannon-Albright LA (2007). Population-based assessment of non-melanoma cancer risk in relatives of cutaneous melanoma probands. J Invest Dermatol, 127(1), 183-8. (Read full article)
    13. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, Leachman SA (2006). Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol, 126(3), 660-6. (Read full article)

    Review

    1. Millsop JW, Heller MM, Eliason MJ, Murase JE (2013). Dermatological medication effects on male fertility. [Review]. Dermatol Ther, 26(4), 337-46. (Read full article)
    2. Leachman SA, Jackson R, Eliason MJ, Larson AA, Bolognia JL (2007). Management of melanoma during pregnancy. [Review]. Dermatol Nurs, 19(2), 145-52, 161. (Read full article)

    Case Report

    1. Eliason MJ, Hansen CB, Hart M, Porter-Gill P, Chen W, Sturm RA, Bowen G, Florell SR, Harris RM, Cannon-Albright LA, Swinyer L, Leachman SA (2007). Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation. Arch Dermatol, 143(11), 1409-12. (Read full article)

    Letter

    1. Houston NA, Secrest AM, Harris RJ, Mori WS, Eliason MJ, Phillips CM, Ferris LK (2016). Patient Preferences During Skin Cancer Screening Examination. [Letter to the editor]. JAMA Dermatol, 152(9), 1052-4. (Read full article)
    2. Clark JJ, Secrest AM, Hull CM, Eliason MJ, Leiferman KM, Gleich GJ, Powell DL (2016). The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review. [Letter to the editor]. J Am Acad Dermatol, 74(6), 1274-6. (Read full article)

  • News & Podcasts

    Podcasts